Back to search
FDAFDA · Food and drugs·Recall number D-0097-2026

Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11

Published October 29, 2025 · Recall initiated: October 21, 2025

Summary

FDA records drug Class II recall D-0097-2026, published October 29, 2025 and initiated October 21, 2025. Recalling firm: Bristol-Myers Squibb Company; Status: Ongoing; Reported quantity: 12,778 total vials; Lot: Lot: 033A23B, Expiry: 4/30/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility.

What to do

Voluntary: Firm initiated · Letter

Get an email if OPDUALAG has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
OPDUALAG
Manufacturer
Bristol-Myers Squibb Company
Distributor
Nationwide in the USA
Lot
Lot: 033A23B, Expiry: 4/30/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11 recalled?

Yes. FDA published recall D-0097-2026 on October 29, 2025. Reported hazard: Lack of Assurance of Sterility.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: OPDUALAG.